Morphic (NASDAQ:MORF) Shares Gap Up to $27.69
Morphic (NASDAQ:MORF) Shares Gap Up to $27.69
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $27.69, but opened at $28.42. Morphic shares last traded at $27.91, with a volume of 128 shares.
Moric Holding，Inc.(纳斯达克代码：Morf-Get Rating)股价在周三开盘前大幅上涨。该股此前收盘报27.69美元，开盘报28.42美元。Moric股票最新报27.91美元，成交量为128股。
Analyst Ratings Changes
分析师评级发生变化
Several research firms recently commented on MORF. BMO Capital Markets reiterated a "buy" rating and issued a $83.00 price objective on shares of Morphic in a research report on Friday, August 5th. Stifel Nicolaus assumed coverage on Morphic in a research report on Tuesday. They set a "buy" rating and a $44.00 price target for the company. Wells Fargo & Company reduced their price objective on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. SVB Leerink initiated coverage on Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price objective for the company. Finally, Royal Bank of Canada decreased their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $64.43.
几家研究公司最近对Morf发表了评论。蒙特利尔银行资本市场在8月5日星期五的一份研究报告中重申了买入评级，并发布了Morphi股票83.00美元的目标价。Stifel Nicolaus在周二的一份研究报告中对Morphi进行了报道。他们为该公司设定了“买入”评级和44.00美元的目标价。富国银行在8月4日(星期四)的一份研究报告中将Morphi的目标价从79.00美元下调至77.00美元，并对该股设定了“增持”评级。SVB Leerink在7月20日(星期三)的一份研究报告中启动了Morphi的报道。他们为该公司设定了“跑赢大盘”的评级和45.00美元的目标价。最后，加拿大皇家银行在8月4日(星期四)的一份研究报告中将Morphi的目标价从76.00美元下调至70.00美元，并对该股设定了“跑赢大盘”的评级。根据MarketBeat.com的数据，八位投资分析师对该股的评级为买入，目前该股的共识评级为买入，共识目标价为64.43美元。
Morphic Price Performance
形态性价比
The stock has a 50-day simple moving average of $26.94 and a 200-day simple moving average of $30.89. The stock has a market cap of $1.10 billion, a PE ratio of -19.66 and a beta of 1.46.
该股的50日简单移动均线切入位为26.94美元，200日简单移动均线切入位为30.89美元。该股市值为11.亿美元，市盈率为-19.66，贝塔系数为1.46。
Institutional Inflows and Outflows
机构资金流入和流出
Morphic Company Profile
形态化的公司简介
(Get Rating)
(获取评级)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
生物制药公司Moric Holding，Inc.发现和开发用于治疗自身免疫、心血管、代谢性疾病以及纤维化和癌症的口服小分子整合素疗法。它的主要候选产品是Morf-057，这是一种A4？7特定的影响炎症的整合素抑制剂，目前处于治疗炎症性肠病的第一阶段临床试验；以及治疗特发性肺纤维化和纤维化疾病的临床前试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Morphic (MORF)
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- 免费获取StockNews.com关于Morphy的研究报告(Morf)
- REV集团在电动汽车世界拥有深厚的护城河
- G-III服装集团有限公司是价值陷阱吗？
- 美国银行看好这两只欧洲酒类股票
- 3低贝塔防御性股票为艰难的市场做准备
- 对于这三只股票来说，这可能是一个值得记住的9月
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
接受Morphy Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Morphi及相关公司评级的每日简明摘要。